SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (NASDAQ:ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working directly with STENDRAⓇ manufacturer Petros Pharmaceuticals, Lemonaid Health is able to offer the fast-acting ED medication at improved pricing. With one in 10 men estimated to h ...

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter ...

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarte ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

KEY TAKEAWAYS23andMe's CEO, Anne Wojcicki, is seeking to take the DNA-testing company private less than three years after it went public in a SPAC deal.Wojcicki holds voting power of 49.99% in the company, so a third-party acquisition is nearly impossible.The company was hit by a large data hack late last year. 23andMe (ME) chief executive Anne Wojcicki is seeking to take the DNA-testing company private less than three years after it went public, the firm said in a Securities and Exchange Commission (SEC) f ...

23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private after its stock price has tumbled more than 95% from its 2021 highs.Wojcicki is working with advisors and plans to begin speaking to possible financing sources and partners, according to a filing with the U.S. Securities and Exchange Commission late Wednesday. She "wishes to maintain control" of the company and will "not be willing to support any alternative transaction," the filing said.The former billionaire co ...

23andMe May Disappear as Public Stock Altayb / Getty Images Battered 23andMe Holding Co. (NASDAQ: ME), its shares driven down to penny stock levels, may disappear from the public markets completely. That is if its CEO can take the company private. If not, 23andMe may run out of money.CEO Anne Wojcicki has told a special committee of the 23andMe board that she will begin to look for funding to buy out public investors. According to an SEC filing, “Ms. Wojcicki also indicated that she wishes to maintain con ...

23andMe新项目介绍 - 23andMe将在AACR年会上展示两个临床阶段项目，分别是23ME-01473和23ME-00610[1] - 23ME-01473是一个针对ULBP6的抗体，通过激活NKG2D和FcγRIIIa来恢复自然杀伤细胞和T细胞对肿瘤的免疫反应[2] - 23ME-00610是一个针对CD200R1的抗体，可增强癌症患者外周血单核细胞的干扰素-γ分泌，提高T和NK细胞的抗肿瘤活性[15]

23andMe公司 - 多位亿万富翁基金经理在2023年第四季度购买了23andMe的股票，尽管股价已经从高峰下跌[1] - 23andMe吸引了亿万富翁投资者的兴趣，尽管股价已经下跌了97%，但亿万富翁对其未来有复苏的期望[3] - 23andMe与GSK签订了一项为期五年的合作协议，GSK支付了2,000万美元的前期费用，同时23andMe还有机会在新药候选品在临床试验中获得成功时获得里程碑付款[5]

23andMe Holding Co.临床试验 - 首位参与者已接受‘1473用于晚期实体肿瘤的一期临床试验[2] - ‘1473通过靶向ULBP6来恢复NK和T细胞的抗肿瘤免疫力[4] 23andMe新药研发 - 23andMe的研究平台发现了新的调查性抗体ULBP6[3] - ULBP6是23andMe验证的第三个药物靶点，进入临床试验不到4年[3]